GlassScriptPhysician profile
Thayer Nasereddin
NPI 1215391701
$4,576.79
in general payments reported to CMS, 2019-2025
28 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.95 · 2020: $55.45 · 2021: $30.66 · 2022: $323 · 2023: $473 · 2024: $1,455 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,471 · Travel and Lodging: $586 · Education: $15.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,471.40 |
| Travel and Lodging | $585.72 |
| Education | $15.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.41 | 2019-2025 | |
| Ovesco Endoscopy USA, INC. | $585.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $424.96 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.45 | 2023-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $329.72 | 2023-2025 | Tremfya, Stelara, Simponi |
| Lumendi LLC | $224.48 | 2025 | |
| Boston Scientific Corporation | $205.09 | 2024-2025 | Wallflex Duodenal, Axios, X-Tack Endoscopic Helix Tacking System |
| Olympus Corporation of The Americas | $187.46 | 2022 | |
| Conmed Corporation | $175.42 | 2024 | Conmed Biliary, Conmed Generators |
| Medtronic, INC. | $131.32 | 2021-2022 | |
| Genzyme Corporation | $116.16 | 2023-2025 | |
| Pfizer INC. | $94.62 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $92.62 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $79.14 | 2023-2025 | |
| Ardelyx, INC. | $67.90 | 2023-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $63.03 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $56.91 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $51.07 | 2023-2024 | Linzess |
| Amgen INC. | $31.24 | 2024-2025 | |
| Qol Medical, LLC | $27.88 | 2024 | Sucraid |
| Novo Nordisk INC | $27.55 | 2025 | Wegovy |
| Laborie Medical Technologies Corp. | $27.52 | 2023 | |
| Braintree Laboratories, INC. | $23.86 | 2024 | Sutab, Suflave |
| Fujifilm Healthcare Americas Corporation | $22.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.07 | 2024 | Iqirvo |
| Sandoz INC. | $16.81 | 2024 | Hyrimoz |
| Celltrion USA INC. | $15.69 | 2024 | Zymfentra |
| Lilly USA, LLC | $13.17 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thayer Nasereddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.